Key indicators: single-crystal X-ray study; T = 294 K; mean (C-C) = 0.003 Å; R factor = 0.041; wR factor = 0.117; data-to-parameter ratio = 17.8.
In the title compound, C 22 H 20 ClN 3 S 2 , the S-bound benzene rings are inclined [dihedral angles = 78.13 (10) and 36.70 (9) ] with respect to the pyrimidine ring. The methylpropyl group occupies a position normal to the pyrimidine ring [N-C-C-C torsion angle = 92.3 (2) ]. In the crystal, supramolecular layers are formed in the bc plane, being consolidated by C-HÁ Á Á andinteractions, the latter between the pyrimidine and S-bound benzene rings [inter-centroid distance = 3.7683 (12) Å ].
Related literature
For the chemotherapeutic activity of pyrimidine derivatives, see: Al-Abdullah et al. (2011); Brunelle et al. (2007) ; Ding et al. (2006) ; Al-Safarjalani et al. (2005) . For a related pyrimidine structure, see: El-Emam et al. (2011) . Table 1 Hydrogen-bond geometry (Å , ).
Experimental
Cg1 is the centroid of the C17-C22 ring.
Symmetry code: (i) Àx þ 1; Ày þ 1; Àz þ 1.
Data collection: CrysAlis PRO (Agilent, 2012); cell refinement: CrysAlis PRO; data reduction: CrysAlis PRO; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 for Windows (Farrugia, 1997) and DIAMOND (Brandenburg, 2006) ; software used to prepare material for publication: publCIF (Westrip, 2010).
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Comment
The chemotherapeutic efficacy of pyrimidine derivatives is related to their ability to inhibit vital enzymes responsible for DNA biosynthesis. Thus, several non-nucleoside pyrimidine derivatives exhibit anti-cancer (Al-Safarjalani et al., 2005 ), anti-viral (Brunelle et al., 2007 Ding et al., 2006) and anti-bacterial activities (Al-Abdullah et al., 2011) . In continuation of our interest in the chemical, pharmacological and structural properties of pyrimidine derivatives (El-Emam et al., 2011) , we synthesized the title compound as a potential chemotherapeutic agent.
With respect to the pyrimidine ring in the title molecule ( Fig. 1) , the S1-and S2-bound benzene rings form dihedral angles of 78.13 (10) and 36.70 (9)°, respectively, indicating orthogonal and splayed orientations, respectively; the dihedral angle between the benzene rings = 69.72 (11)°. The methylpropyl group occupies a position normal to the pyrimidine ring with the N2-C4-C5-C6 torsion angle being 92.3 (2)°.
In the crystal packing, supramolecular layers, consolidated by C-H···π, Table 1 , and π-π interactions between the pyrimidine and the S1-bound benzene rings [ring centroid(N1,N2,C1-C4)···centroid(C10-C15) distance = 3.7683 (12) Å, angle of inclination = 5.52 (10)° for symmetry operation: 1 -x, -1/2 + y, 3/2 -z], are formed in the bc plane, Fig. 2 .
Experimental
To a solution of 2-(4-chlorobenzylsulfanyl)-6-chloro-4-(2-methylpropyl)pyrimidine-5-carbonitrile (705 mg, 2 mmol) in dry pyridine (3 ml), thiophenol (220 mg, 2 mmol) was added and the mixture was heated under reflux for 6 h. On cooling, the solvent was distilled off in vacuo and water (5 ml) was added to the residue. The separated precipitate was filtered, washed with cold water, dried and crystallized from ethanol to yield 724 mg (85%) of the title compound as colourless crystals. M.pt: 394-396 K. Crystals for the X-ray analysis were obtained by slow evaporation of a solution of the title compound in CHCl 3 :EtOH (1:1, 5 ml) held at room temperature.
Refinement
Carbon-bound H-atoms were placed in calculated positions [C-H = 0.93 to 0.98 Å, U iso (H) = 1.2-1.5U eq (C)] and were included in the refinement in the riding model approximation.
Computing details
Data collection: CrysAlis PRO (Agilent, 2012); cell refinement: CrysAlis PRO (Agilent, 2012); data reduction: CrysAlis PRO (Agilent, 2012); program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 for Windows (Farrugia, 1997) and DIAMOND (Brandenburg, 2006) ; software used to prepare material for publication: publCIF (Westrip, 2010). A view in projection down the b axis of the unit-cell contents for the title compound. The C-H···π and π-π interactions are shown as brown and purple dashed lines, respectively. Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > σ(F 2 ) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
2-[(4-Chlorobenzyl)sulfanyl]-4-(2-methylpropyl)-6-(phenylsulfanyl)pyrimidine-5-carbonitrile
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 )
x y z U iso */U eq S1 0.54678 (4) 0.70944 (6) (14) 0.0089 (9) −0.0012 (9) −0.0261 (11) C17 0.0493 (9) 0.0534 (9) 0.0558 (9) 0.0030 (7) 0.0048 (7 C2-S1-C10 102.20 (8) C11-C10-S1 119.80 (16) C1-S2-C16 100.23 (9) C15-C10-S1 120.09 (15) C2-N1-C1 115.71 (14) C10-C11-C12 119.1 (2) C4-N2-C1 116.30 (14) C10-C11-H11 120.5 N1-C1-N2 127.73 (15) C12-C11-H11 120.5 N1-C1-S2 118.00 (12) C13-C12-C11 120.8 (2) 
